NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn ... Following this news, the price of Cassava's common ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.14% ...

In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $154.92 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or ...

Nano Labs Ltd (NASDAQ:NA) stock is one of the top performers on the Nasdaq today, up 38.3% at $13.28 at last glance, after the semiconductor name announced a $50 million Bitcoin (BTC) purchase plan ...

Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...

Research analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Cassava Sciences in a research report issued on Tuesday, November 26th. HC Wainwright analyst V. Bernardino ...

Pipeline and regulatory updates are in focus in the biotech sector. Among these, BridgeBio Pharma, Inc. BBIO gained on ...

Given Cassava's poor clinical prospects and lack of revenue, I recommend selling SAVA stock and looking for better biotech opportunities. Based on Simufilam's clinical trial history and concerns ...

Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.